Xenetic Biosciences Inc
NASDAQ:XBIO

Watchlist Manager
Xenetic Biosciences Inc Logo
Xenetic Biosciences Inc
NASDAQ:XBIO
Watchlist
Price: 2.65 USD -4.19% Market Closed
Market Cap: $6.1m

Operating Margin

-115.8%
Current
Improving
by 84.8%
vs 3-y average of -200.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-115.8%
=
Operating Income
$-3.3m
/
Revenue
$2.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-115.8%
=
Operating Income
$-3.3m
/
Revenue
$2.9m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Xenetic Biosciences Inc
NASDAQ:XBIO
6.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-115.8%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Xenetic Biosciences Inc
Glance View

Market Cap
6.1m USD
Industry
Biotechnology

Xenetic Biosciences, Inc. is a biopharmaceutical company, which engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2016-11-07. The firm is focused on progressing XCART, a personalized Chimeric Antigen Receptor (CAR) T platform technology engineered to target patient- and tumor-specific neoantigens. The firm is advancing cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient’s malignant tumor cells, for the treatment of B-cell lymphomas. The firm's product pipeline includes XCART platform, Polyxen and ErepoXen (PSA-EPO). PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. The company uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties.

XBIO Intrinsic Value
3.28 USD
Undervaluation 19%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-115.8%
=
Operating Income
$-3.3m
/
Revenue
$2.9m
What is Xenetic Biosciences Inc's current Operating Margin?

The current Operating Margin for Xenetic Biosciences Inc is -115.8%, which is above its 3-year median of -200.6%.

How has Operating Margin changed over time?

Over the last 3 years, Xenetic Biosciences Inc’s Operating Margin has increased from -453.5% to -115.8%. During this period, it reached a low of -453.5% on Aug 30, 2022 and a high of -115.8% on Oct 30, 2025.

Back to Top